The expression of Cav3.1, with a positive correlation with autophagy biomarkers related to melanoma progression, prognosis, and resistance acquisition to BRAFi, can lead to the development of new therapeutic strategies by which TTCCs are blocked in order to deal with the development and emergence of metastatic melanoma. The gene discussed is CACNA1G; the disease is metastatic melanoma.